Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.
As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.
Biomedical Advanced Research and Development Authority (BARDA)
BARDA continues to solicit proposals for the development of diagnostic assays and therapeutics for COVID-19 and encourages applicants to participate in a TechWatch meeting prior to submitting a white paper or full proposal in response to its current Broad Agency Announcement
Topic: Proposals for diagnostic assay development are solicited under Area of Interest (AOI) 7.7; projects to develop COVID-19 therapeutics, including direct-acting antivirals and host-directed therapeutics, may be submitted under AOI 9.2; and projects to develop and demonstrate innovations and enhancements to pharmaceutical manufacturing platforms to support the development of vaccines and therapeutics for COVID-19 can be submitted under AOI 17
Description: BARDA DRIVe’s current EZ-BAA solicitation (BAA-20-100-SOL-0002) includes an Area of Interest (AOI) that is relevant for applicants developing technologies for the early detection of COVID-19 through monitoring of a person’s health status. Through AOI #001 “Early Notification to Act, Control and Treat (ENACT),” DRIVe is seeking technologies and methods to a) identify and characterize biological, behavioral, and physiological signatures that can signal infection or injury before the onset of noticeable symptoms and b) technologies that provide early health status information to medical care providers. Applications may but do not have to focus on COVID-19 as a potential use case.
Topics: Early detection of infection through biological, behavioral, and physiological signatures
Due Dates: Applications are accepted on a rolling basis until 2/3/2023.
Budget: Up to $749,000
While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel. A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.
National Institutes of Health (NIH)
Notices of Special Interest (NOSI)
Multiple NIH Institutes have issued Notices of Special Interest (NOSIs) to provide funding for research topics related to COVID-19. For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.
Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)
Description: The NIH has issued a funding opportunity announcement to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative through the U01 mechanism. Proposals are requested for two-year Testing Research Projects that will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. Collectively, projects supported under these funding opportunities will join the RADxSM-UP consortium of community-engaged research projects across the United States to understand and mitigate COVID-19 health disparities, and to test interventions that improve the reach, uptake, and sustainability of COVID-19 testing in various settings.
Topics: Detailed lists of research objectives and specific areas of research interest are provided in the funding opportunity announcement at the above link.
Due Dates: 7/7/2021
Budget: $750,000 per year in direct costs (maximum project period of 2 years)
- PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
- PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.
Topics: NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.
Due Date: Rolling until 5/1/2021
Budget: Limited to no more than that amount of the current parent award.
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)
Description: This program will support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age). Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.
Topics: This program will support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age). Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.
- Mechanisms regulating the generation and maintenance of T and B cell memory;
- Molecular mechanisms of innate immunity, including trained immunity; Effect of the microbiota on host immune development and response; Mechanisms of tissue-specific and mucosal immunity;
- Role and mechanisms of action of adjuvants/immune-potentiating molecules or compounds for improving protective immune responses in children;
- Impact of sex differences on innate and adaptive immune development and function; Impact of maternal factors on immune system development in early life that include examination of longer-term effects in the child;
- Mechanism by which environmental exposures affect the functionality of the pediatric immune system;
- Mechanisms regulating exhaustion of the immune response to chronic infection or exposure, and impact on vaccine responses;
- Metabolic and/or epigenetic regulation of the pediatric immune response;
-Key factors impacting the pediatric immune response and efficacy of HIV vaccine candidates and other HIV-prevention strategies;
-Broadly neutralizing antibody development during pediatric immune maturation;
-Longitudinal imaging of immune cell dynamics and immune responses to vaccines or other prevention strategies in the pediatric population;
-Development of mucosal immunity in the context of vaccine/prevention strategies;
-Studies testing or proposing development of drugs/vaccines to prevent infection that is specific to the pediatric population.
Due Dates: 6/18/2021
Budget: $500,000 direct costs per year
Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
Description: NIAID has issued a Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines that are able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.
Topics: Particular areas of interest include:
- Identification of broadly reactive B- and T-cell epitopes;
- Structural studies of CoV proteins related to designing novel, effective immunogens;
- Rational design of CoV immunogens to elicit broadly neutralizing, durable antibodies against multiple CoVs;
- Studies to understand the role of antigen-specific T cell responses in immunity to CoVs, including strategies to induce T-cell immunity;
- Studies to identify correlates of protection against CoVs following natural infection or vaccination;
- Studies to understand vaccine-induced responses across the life span, including investigation of age- or sex-related effects on vaccine efficacy;
- Studies to understand the impact of previous exposure to CoVs on subsequent vaccine responses;
- Studies to identify antigen/adjuvant combinations to induce potent and broad protection against multiple CoVs;
- Development of multi-valent and next-generation vaccine platforms/strategies to provide durable immunity to multiple CoVs, and that are suitable for use in vulnerable populations;
- Iterative studies and head-to-head comparisons of candidate vaccines in relevant preclinical models are encouraged to advance the most promising vaccine candidates;
- Strategies to direct protective immune responses to relevant tissues, such as mucosal sites.
Due Dates: 6/11/2021
Budget: Not limited
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)
Description: The National Institute of Allergy and Infectious Diseases (NIAID) has released a new funding opportunity to provide personal protective equipment to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and the Coronavirus Aid, Relief and Economic Security (CARES) Act.
Topics: Purchase of personal protective equipment for use in COVID-19 clinical trials or clinical studies
Due Date: Applications are accepted on a rolling basis
Budget: Not limited
National Institute on Drug Abuse (NIDA)
Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Description:NIDA has issued this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Proposed revisions may either be within the scope of the existing NIDA grant or expand its scope.
Topics: An extensive list of research areas of interest is provided in the Notice of Special Interest at the above link.
Due Date: Applications will be accepted on a rolling basis until 3/31/2022.
Budget: $100,000 in direct costs per year (maximum project period of 2 years)
National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS)
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
Description: NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions. While there is no obvious indication of adverse events or impacts of the use of COVID-19 vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions.
Topics: This NOSI encourages, but is not limited to, research applications focused on:
- Susceptibility to, prevalence, risk assessment, and clinical management of COVID-19 among patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- The impacts of drugs or other targeted therapies that are used to treat diseases within the mission of NIAMS on susceptibility, severity, and management of COVID-19;
- Health disparities and social/behavioral factors that contribute to risk of infection, organ injury and adverse outcomes in COVID-19 patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- Impact of COVID-19 vaccination of patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
- Characterization of long-term post-acute sequelae occurring in recovered COVID-19 patients with co-existing rheumatic, musculoskeletal, and/or skin diseases;
- Characterization of NIAMS-mission related long-term post-acute sequelae (e.g. muscle pain, joint pain, biobehavioral changes, skin rash, arthritis, etc.) occurring in recovered COVID-19 patients.
Due Date: February 5 through November 18, 2021
Budget: Not Specified
National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is soliciting applications for Emergency Competitive Revisions to Existing NIH Awards (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients for clinical studies and trials in support of COVID-19 therapeutic interventions. To be eligible, the parent CTSA Program award on which the revision application is based must be active when the application is submitted. The proposed project and budget periods must be within the currently approved project period for the existing parent award.
Topics: Clinical studies and trials of COVID-19 therapeutic interventions
Due Dates: Applications are accepted on a rolling basis through 8/16/2024.
Budget: Not specified
NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need
Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.
PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
Due Dates: 7/9/2021
Budget: $400,000 – $750,000
PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)
Due Dates: 7/9/2021
Budget: $275,000 (direct costs)
Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.
Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award
Depart of Defense (DoD)
Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) Commercial Solutions Opening
Description: The DAF ACT Commercial Solutions Opening (CSO) is a contract opportunity that seeks innovative, commercial technologies that propose new solutions and/or potentially new capabilities that fulfill requirements, close capability gaps, or provide potential technological advancements in support of the COVID-19 Response Acquisition Task Force mission to provide relief, resilience, recovery, and stability to the nation in response to the COVID-19 pandemic. This CSO may have areas of interest (AoIs) that result in an award of prototype projects, which include not only commercially available technologies fueled by commercial or strategic investment but also concept demonstrations, pilots, and agile development activities that can incrementally improve commercial technologies, existing government-owned capabilities, and/or concepts for broad defense and/or public application(s). Solution Briefs will be solicited by the posting of DAF ACT AoIs within predetermined Mission Focus Areas that identify generalized areas of need. All AoIs will be posted as amendments to the CSO solicitation at https://beta.sam.gov/.
Topics: The seven Mission Focus Areas for this contract opportunity are as follows:
- Screening & Diagnostics
- Logistics (security and protection, supply chain protection and assessment, etc.)
- Medical (telehealth, medical capacity, and sustainment, medical supplies and equipment, etc.)
- Other – Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic
Due Date: Various (see individually published AoIs for details)
Budget: Not specified
US Department of Agriculture (USDA)
National Institute of Food and Agriculture (NIFA)
In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.
Agriculture and Food Research Initiative (AFRI)
Topics: Focus areas of interest include, but are not limited to the following:
- Animal Nutrition, Growth and Lactation (A1231)
- Critical Agricultural Research and Extension (CARE) (A1701)
- Diseases of Agricultural Animals (A1221)
- Food Safety and Defense (A1332)
- Foundational Knowledge of Plant Products (A1103)
- Economics, Markets, and Trade (A1641)
Due Date: Varies by Program
US Department of State
U.S. Department of State, Office to Monitor and Combat Trafficking in Persons, International Programs Section
2020 TIP Office Annual Program Statement to Address Impacts of COVID-19
Description: The Department of State’s Office to Monitor and Combat Trafficking in Persons (TIP Office) has an open competition for funding to address the impacts of COVID-19 on efforts to combat human trafficking and support government measures to counter human trafficking. Applicants are encouraged to propose activities that will help organizations and partner governments continue to combat trafficking in persons despite the challenges presented by the COVID-19 pandemic.
Topics: Examples of activities include, but are not limited to:
- Supporting research and analysis to identify how COVID19 and governments’ responses have impacted human trafficking trends at the local, national, regional, or global level
- Assisting governments to better screen and identify victims of trafficking among communities made more vulnerable as a result of COVID-19 and stay-at-home orders.
- Working closely with source and destination governments to increase human trafficking screening procedures in the workplace, particularly for migrant workers who face increased vulnerability to exploitation by traffickers as the economy reopens
- Facilitating the safe self-identification of victims
- Supporting collaborative cross-border case management with law enforcement by assisting governments with the repatriation of identified survivors of trafficking and facilitating virtual court systems and witness testimony to support prosecutions during a time of decreased or closed state services
- Providing access to services and resources for victims and survivors that may have decreased as a result of COVID-19 and government responses
- Addressing the surge in traffickers using the internet to abuse their victims and working with governments to identify and crackdown on these types of cybercrimes
Due Date: 6/30/2021
Budget: $100,000 minimum
Other US Funding Sources
COVID-19 Early Treatment Fund (CETF)
Description: The CETF focuses on funding outpatient clinical trials to repurpose existing drugs for effective COVID-19 treatment. The goal is to rapidly test and implement the use of drugs that have already gone through extensive safety testing and are currently approved and marketed for other indications, as these will be much faster to mass-produce than new drugs. The CETF is funding an array of well-designed outpatient clinical trials in parallel to quickly identify which existing drugs work to treat COVID-19. All funded trials go through a rigorous review process by the organization’s Scientific Advisory Board before being approved. The CETF is interested in trial designs that incorporate next-generation DNA sequencing to identify virus variants and human variants that lead to better or worse outcomes in order to triage patients.
Topics: Outpatient clinical trials of existing drugs (marketed for other indications) to treat COVID-19
Due Date: Not Specified
Budget: Not Specified
ImpactAssets and Stop the Spread
Description: Stop the Spread’s COVID Response Program is keenly focused on working with companies and organizations—large and small—to spur development of PPE for both medical and non-medical use, novel testing solutions, widely-accessible therapeutics and digital health solutions to address the needs of underserved communities and vulnerable populations.
- Hyperlocal Support
- Health Services
Due Date: Not Specified
Budget: Not Specified
Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.
Topics: The Accelerator is seeking partners for the following activities:
- Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
- Developing drugs or monoclonal antibodies that pass initial screening.
- Scaling up production and commercialization of successful drugs and monoclonal antibodies.
Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000
Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.
Topics: All COVID-19 related science
Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 – $500,000
Global Innovation Fund
Description: The Global Innovation Fund is a non-profit innovation fund that invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people, i.e., those living on less than $5 a day. For-profit companies located anywhere in the world can apply for funding for projects that address COVID-19 in developing countries. GIF supports innovators at all stages of their life cycle, from start-up and pilot-testing through to larger-scale implementation.
Topics: Innovations to assist with COVID-19 response and related issues affecting people living on less than $5 a day in developing countries.
Due Dates: Applications are accepted on a rolling basis
Budget: $50,000 to $15,000,000 depending upon project stage and needs. Grants are available to for-profit companies where appropriate, but other forms of investment are also used.
UK Research and Innovation (UKRI)
Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. You will need to show that you can start work within 4 weeks of the funding being confirmed.
Topics: Short-term projects (12-18 months) addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.
Due Date: Ongoing
Budget: 80% of the full economic cost
Description: UKRI has made seed funding available for urgent COVID-19-related projects with a maximum duration of 6 months and a clear path forward once the urgent phase is completed. Urgent applications will be reviewed on a two-week basis with the expectation that the project would start within a month. Non-urgent COVID-19 proposals can be submitted through UKRI’s standard grant routes.
Topics: Urgent projects include those involving the collection of data or samples or rapid turnaround of initial research that is essential to secure future research or inform urgent policy or national/international decisions.
Due Dates: Applications are accepted on a rolling basis.
Description: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural, and environmental impacts of the COVID-19 outbreak.
Topics: An extensive list of research questions can be found at https://www.ukri.org/files/research-questions-for-covid-19/. These questions focus on various areas, including:
- COVID-19 treatments
- Contact tracing
- Data availability and use
- Modeling and prediction
- Accelerated use of AI and automation
- National security and geopolitics
- Behavioral insights
Due Dates: None. Applications are accepted on a rolling basis.
Budget: Not specified